Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 3
1978 11
1979 10
1980 211
1981 505
1982 652
1983 541
1984 659
1985 703
1986 746
1987 914
1988 1009
1989 1103
1990 1190
1991 1202
1992 1329
1993 1475
1994 1545
1995 1607
1996 1786
1997 1878
1998 1950
1999 1951
2000 2074
2001 2173
2002 2353
2003 2606
2004 2818
2005 3427
2006 3759
2007 4036
2008 4659
2009 5263
2010 5901
2011 6373
2012 6725
2013 7136
2014 7238
2015 7164
2016 7029
2017 6889
2018 6991
2019 6935
2020 5019
2021 10
Text availability
Article attribute
Article type
Publication date

Search Results

116,337 results
Results by year
Filters applied: . Clear all
Page 1
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. Cramer PE, et al. Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9. Science. 2012. PMID: 22323736 Free PMC article.
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Dave CV, et al. Ann Intern Med. 2019 Aug 20;171(4):248-256. doi: 10.7326/M18-3136. Epub 2019 Jul 30. Ann Intern Med. 2019. PMID: 31357213 Free PMC article.
OBJECTIVE: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists. ...Patients were age …
OBJECTIVE: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those i …
Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.
Wang C, Niederstrasser H, Douglas PM, Lin R, Jaramillo J, Li Y, Oswald NW, Zhou A, McMillan EA, Mendiratta S, Wang Z, Zhao T, Lin Z, Luo M, Huang G, Brekken RA, Posner BA, MacMillan JB, Gao J, White MA. Wang C, et al. Nat Commun. 2017 Dec 22;8(1):2270. doi: 10.1038/s41467-017-02332-3. Nat Commun. 2017. PMID: 29273768 Free PMC article.
Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel compounds that promote autophagolysosomal activity. ...
Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel …
Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fralick M, et al. Ann Intern Med. 2019 Feb 5;170(3):155-163. doi: 10.7326/M18-0567. Epub 2019 Jan 1. Ann Intern Med. 2019. PMID: 30597484 Free PMC article.
The rate of the primary outcome was similar for canagliflozin (2.2 events per 1000 person-years) and GLP-1 agonists (2.3 events per 1000 person-years), with an overall HR of 0.98 (95% CI, 0.75 to 1.26). ...CONCLUSION: In this study of middle-aged patients with type 2 diabe …
The rate of the primary outcome was similar for canagliflozin (2.2 events per 1000 person-years) and GLP-1 agonists (2.3 events per 1 …
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Patorno E, et al. BMJ. 2018 Feb 6;360:k119. doi: 10.1136/bmj.k119. BMJ. 2018. PMID: 29437648 Free PMC article.
OBJECTIVE: To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used i …
OBJECTIVE: To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 di …
An overview of the cannabinoid type 2 receptor system and its therapeutic potential.
Bie B, Wu J, Foss JF, Naguib M. Bie B, et al. Curr Opin Anaesthesiol. 2018 Aug;31(4):407-414. doi: 10.1097/ACO.0000000000000616. Curr Opin Anaesthesiol. 2018. PMID: 29794855 Free PMC article. Review.
Treatment for mild cognitive impairment: systematic review.
Cooper C, Li R, Lyketsos C, Livingston G. Cooper C, et al. Br J Psychiatry. 2013 Sep;203(3):255-64. doi: 10.1192/bjp.bp.113.127811. Br J Psychiatry. 2013. PMID: 24085737 Free PMC article. Review.
Extragonadal Actions of FSH: A Critical Need for Novel Genetic Models.
Kumar TR. Kumar TR. Endocrinology. 2018 Jan 1;159(1):2-8. doi: 10.1210/en.2017-03118. Endocrinology. 2018. PMID: 29236987 Free PMC article. Review.
Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.
Arnsten AF, Girgis RR, Gray DL, Mailman RB. Arnsten AF, et al. Biol Psychiatry. 2017 Jan 1;81(1):67-77. doi: 10.1016/j.biopsych.2015.12.028. Epub 2016 Jan 18. Biol Psychiatry. 2017. PMID: 26946382 Free PMC article. Review.
Research in both academia and the pharmaceutical industry has led to the development of selective D(1) agonists, e.g., the first full D(1) agonist, dihydrexidine, which at low doses improved working memory in monkeys. ...These data, however, have spurred efforts toward the …
Research in both academia and the pharmaceutical industry has led to the development of selective D(1) agonists, e.g., the first full …
PPARβ/δ-agonist GW0742 ameliorates dysfunction in fatty acid oxidation in PSEN1ΔE9 astrocytes.
Konttinen H, Gureviciene I, Oksanen M, Grubman A, Loppi S, Huuskonen MT, Korhonen P, Lampinen R, Keuters M, Belaya I, Tanila H, Kanninen KM, Goldsteins G, Landreth G, Koistinaho J, Malm T. Konttinen H, et al. Glia. 2019 Jan;67(1):146-159. doi: 10.1002/glia.23534. Epub 2018 Nov 19. Glia. 2019. PMID: 30453390 Free PMC article.
116,337 results
Jump to page
Feedback